-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.3%
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 1.3%
ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating)'s stock price traded up 1.3% on Friday . The company traded as high as $6.08 and last traded at $6.08. 818 shares were traded during mid-day trading, a decline of 76% from the average session volume of 3,468 shares. The stock had previously closed at $6.00.
ProMIS Neurosciences Trading Up 1.3 %
The firm has a market capitalization of $52.16 million, a PE ratio of -3.32 and a beta of 0.64. The company has a 50-day simple moving average of $5.81.
Get ProMIS Neurosciences alerts:Hedge Funds Weigh In On ProMIS Neurosciences
An institutional investor recently bought a new position in ProMIS Neurosciences stock. Ieq Capital LLC purchased a new position in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,191 shares of the company's stock, valued at approximately $240,000. Ieq Capital LLC owned 0.46% of ProMIS Neurosciences at the end of the most recent quarter. Institutional investors own 0.14% of the company's stock.
ProMIS Neurosciences Company Profile
(Get Rating)ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
See Also
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (PMN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating)'s stock price traded up 1.3% on Friday . The company traded as high as $6.08 and last traded at $6.08. 818 shares were traded during mid-day trading, a decline of 76% from the average session volume of 3,468 shares. The stock had previously closed at $6.00.
納斯達克股票代碼：PMN-GET Rating)上週五股價上漲1.3%，盤中一度漲至6.08美元，最新報6.08美元。午盤成交量為818股，較3,468股的平均成交量下跌76%。此前該股收盤價為6.00美元。
ProMIS Neurosciences Trading Up 1.3 %
Promis神經科學公司股價上漲1.3%
The firm has a market capitalization of $52.16 million, a PE ratio of -3.32 and a beta of 0.64. The company has a 50-day simple moving average of $5.81.
該公司市值為5,216萬美元，市盈率為-3.32，貝塔係數為0.64。該公司的50日簡單移動均線切入位為5.81美元。
Hedge Funds Weigh In On ProMIS Neurosciences
對衝基金參與PROMIS神經科學
An institutional investor recently bought a new position in ProMIS Neurosciences stock. Ieq Capital LLC purchased a new position in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,191 shares of the company's stock, valued at approximately $240,000. Ieq Capital LLC owned 0.46% of ProMIS Neurosciences at the end of the most recent quarter. Institutional investors own 0.14% of the company's stock.
一家機構投資者最近買入了Promis神經科學股票的新頭寸。根據IEQ Capital LLC最近提交給美國證券交易委員會的文件，該公司在第三季度購買了Promis NeuroScience，Inc.(納斯達克代碼：PMN-GET Rating)的新股票頭寸。該機構投資者購買了39,191股該公司股票，價值約240,000美元。截至最近一個季度末，IEQ Capital LLC擁有PROMIS神經科學公司0.46%的股份。機構投資者持有該公司0.14%的股票。
ProMIS Neurosciences Company Profile
Promis神經科學公司簡介
ProMIS Neurosciences, Inc discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Promis神經科學公司發現和開發用於治療神經退行性疾病的精確醫學解決方案，主要是加拿大的阿爾茨海默病(AD)、肌萎縮側索硬化症(ALS)和多系統萎縮(MSA)。該公司的專有發現平臺包括PROMIS和Collective座標算法，用於預測錯誤摺疊蛋白質分子表面上被稱為疾病特異性表位的新靶點。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ProMIS Neurosciences (PMN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- 免費獲取StockNews.com關於Promis神經科學(PMN)的研究報告
- MarketBeat：回顧一週11/14-11/18
- 目標的雙重底部可能剛剛得到確認
- 美聯儲能漲到多高？如何進行交易
- Verra移動庫存已返回空間站
- ASML的11月拉力賽有後勁嗎？
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受PROMIS神經科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Promis神經科學和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧